Braidwell LP Lowers Stake in Dyne Therapeutics, Inc. $DYN

Braidwell LP cut its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 45.2% during the second quarter, Holdings Channel.com reports. The fund owned 921,598 shares of the company’s stock after selling 760,400 shares during the period. Braidwell LP’s holdings in Dyne Therapeutics were worth $20,469,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics during the first quarter worth approximately $26,000. Strs Ohio purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at approximately $51,000. Allworth Financial LP purchased a new stake in shares of Dyne Therapeutics in the second quarter valued at approximately $62,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth approximately $84,000. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. The trade was a 83.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,139,196 shares of company stock valued at $99,449,852 in the last ninety days. Insiders own 9.46% of the company’s stock.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $25.14 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics, Inc. has a 1 year low of $11.92 and a 1 year high of $27.31. The firm has a market capitalization of $4.69 billion, a PE ratio of -7.55 and a beta of 1.08. The business’s 50 day moving average price is $24.65 and its 200-day moving average price is $20.26.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on DYN shares. Sanford C. Bernstein lifted their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. TD Cowen assumed coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Wall Street Zen lowered shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Finally, Morgan Stanley cut their target price on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.42.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.